Greenwich Wealth Management LLC cut its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,004 shares of the company’s stock after selling 114 shares during the quarter. Greenwich Wealth Management LLC’s holdings in Johnson & Johnson were worth $710,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in the company. Magnolia Capital Management Ltd. boosted its stake in Johnson & Johnson by 0.5% in the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after acquiring an additional 55 shares in the last quarter. Howard Financial Services LTD. lifted its stake in shares of Johnson & Johnson by 2.1% during the first quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after buying an additional 57 shares during the period. American Financial Advisors LLC lifted its stake in shares of Johnson & Johnson by 2.1% during the first quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock worth $481,000 after buying an additional 57 shares during the period. Kwmg LLC lifted its stake in shares of Johnson & Johnson by 2.6% during the first quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after buying an additional 59 shares during the period. Finally, Corsicana & Co. lifted its stake in shares of Johnson & Johnson by 0.4% during the first quarter. Corsicana & Co. now owns 15,553 shares of the company’s stock worth $2,756,000 after buying an additional 60 shares during the period. 68.59% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.35% of the stock is owned by corporate insiders.
Johnson & Johnson Trading Down 0.8 %
Shares of Johnson & Johnson stock opened at $163.00 on Tuesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The firm has a fifty day moving average price of $172.94 and a 200 day moving average price of $174.36. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The stock has a market cap of $428.56 billion, a PE ratio of 23.73, a price-to-earnings-growth ratio of 3.12 and a beta of 0.59.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the previous year, the company earned $2.48 earnings per share. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.77%. Johnson & Johnson’s payout ratio is 65.79%.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on JNJ. Daiwa Capital Markets began coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating for the company. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. UBS Group lowered their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Citigroup lowered their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Finally, Morgan Stanley raised their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday, July 8th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $189.89.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.